Watch on YouTube – Watch on Vimeo

Dr. John-Paul Bogers, M.D.

John-Paul Bogers, M.D. (CEO) is a professor of Histology and Cell Biology at the University of Antwerp. He is also a founder or board member of 6 Belgian and foreign (South Africa) companies (all medical or technology driven).
John-Paul was principal investigator of three large clinical trials on molecular biomarkers, successfully submitted applications for 20 national, industry funded and international projects (including 3 EU funded programs). He was supervisor of 13 graduated PhD students and published > 150 scientific articles.

• Introduction and Guest Background 0:00
  • Dr. Barrett introduces Dr. John Paul Bogers, a histopathologist and CEO of Elmedix, who has developed a technology to treat pancreatic cancer with hyperthermia.
  • Dr. Barrett mentions the previous episode with Dr. Jason Williams, which introduced cutting-edge technology for treating cancer.
  • Dr. Barrett welcomes Dr. Bogers and expresses excitement about discussing his technology.
  • Dr. Bogers thanks Dr. Barrett for the invitation and shares his background as a medical doctor, histopathologist, and molecular pathologist.
• Formation and Focus of Elmedix 2:46
  • Dr. Bogers explains the formation of Elmedix in 2015 with a friend, an engineer, to treat advanced metastatic cancer.
  • The company initially focused on pancreatic cancer due to its high metastasis rate and personal reasons for Dr. Bogers.
  • Dr. Bogers describes the development process, including animal testing and treating six dogs with positive results.
  • The company conducted human trials and is now at the end of the first in-human trial with promising safety and efficacy data.
• Hyperthermia Treatment Mechanism 5:36
  • Dr. Bogers details the hyperthermia treatment, which involves heating the entire body to 41.5 degrees Celsius (106.5 degrees Fahrenheit) using a high-velocity hot air flow.
  • The treatment uses sensors to ensure homogeneous heating and avoid hot spots.
  • Dr. Bogers explains the rationale behind treating the entire body, especially for metastasized cancer, to reach all metastases.
  • The treatment aims to enhance the immune system and increase the efficacy of chemotherapy.
• Challenges and Future Directions 23:59
  • Dr. Bogers discusses the challenges of hyperthermia, including the need for full anesthesia and the potential for future sedation.
  • The treatment is currently administered in an operating theater under full anesthesia for safety reasons.
  • Dr. Bogers mentions the potential for using AI to predict internal temperatures and reduce the need for liver sensors.
  • The company is exploring the use of hyperthermia as a maintenance therapy and its potential to transform cancer into a chronic disease.
• Integration with Other Oncology Treatments 41:08
  • Dr. Bogers explains the synergistic effects of hyperthermia with chemotherapy, radiotherapy, and targeted treatments.
  • The treatment enhances the efficacy of chemotherapy by making tumor cells more vulnerable.
  • Hyperthermia also aids in radiotherapy and has been proven effective in treating breast, prostate, and sarcoma cancers.
  • The company plans to explore the synergistic effects of hyperthermia with various treatments to enhance their efficacy.
• Efficacy and Regulatory Approval 41:20
  • Dr. Bogers shares the efficacy data from the first in-human trial, which shows a good safety profile and interesting efficacy data.
  • The company is in discussions with the FDA to obtain breakthrough status and expedite market approval.
  • Dr. Bogers emphasizes the importance of conducting trials according to international standards to ensure credibility.
  • The company aims to obtain regulatory approval by 2028-2029 and is exploring potential offshore markets for early adoption.
• Potential for Broader Applications 49:52
  • Dr. Bogers discusses the potential for hyperthermia to treat other cancers, including breast, melanoma, and prostate cancer.
  • The treatment could also be used for blood-borne cancers, although more research is needed.
  • Dr. Bogers highlights the broader implications of hyperthermia in medicine, including its potential to enhance the efficacy of various treatments.
  • The company aims to integrate hyperthermia into standard oncology treatment protocols to improve patient outcomes.
• Challenges and Future Outlook 53:48
  • Dr. Bogers expresses frustration with the regulatory approval process and the need for continued funding.
  • The company is exploring potential investors and partnerships to support its research and development efforts.
  • Dr. Bogers emphasizes the importance of the technology in improving patient quality of life and reducing the burden of cancer.
  • The company aims to make hyperthermia a standard treatment option for various cancers, enhancing the overall efficacy of oncology treatments.

Special Offer: Save 15% Using Code “SBPOD” At Checkout

1. Follow us on all social platforms (Facebook, Instagram, and LinkedIn)
2. Subscribe to our YouTube channel
3. Comment “Let’s Spelunk” on any Season 6 YouTube video to enter

YouTube: https://www.youtube.com/@podofinquiry
Facebook: https://www.facebook.com/podofinquiry/
Instagram: https://www.instagram.com/podofinquiry/
LinkedIn: https://www.linkedin.com/in/stephen-barrett-92776a51/